165 related articles for article (PubMed ID: 12745272)
21. Multiple myeloma: monoallelic deletions of the tumor suppressor genes TP53 and RB1 in long-term follow-up.
Carlebach M; Amiel A; Gaber E; Radnay J; Manor Y; Fejgin M; Lishner M
Cancer Genet Cytogenet; 2000 Feb; 117(1):57-60. PubMed ID: 10700868
[TBL] [Abstract][Full Text] [Related]
22. CDK4 and MDM2 gene alterations mainly occur in highly proliferative and aggressive mantle cell lymphomas with wild-type INK4a/ARF locus.
Hernández L; Beà S; Pinyol M; Ott G; Katzenberger T; Rosenwald A; Bosch F; López-Guillermo A; Delabie J; Colomer D; Montserrat E; Campo E
Cancer Res; 2005 Mar; 65(6):2199-206. PubMed ID: 15781632
[TBL] [Abstract][Full Text] [Related]
23. p16/p14(ARF) cell cycle regulatory pathways in primary neuroblastoma: p16 expression is associated with advanced stage disease.
Omura-Minamisawa M; Diccianni MB; Chang RC; Batova A; Bridgeman LJ; Schiff J; Cohn SL; London WB; Yu AL
Clin Cancer Res; 2001 Nov; 7(11):3481-90. PubMed ID: 11705866
[TBL] [Abstract][Full Text] [Related]
24. Genomic aberrations of MDM2, MDM4, FGFR1 and FGFR3 are associated with poor outcome in patients with salivary gland cancer.
Ach T; Schwarz-Furlan S; Ach S; Agaimy A; Gerken M; Rohrmeier C; Zenk J; Iro H; Brockhoff G; Ettl T
J Oral Pathol Med; 2016 Aug; 45(7):500-9. PubMed ID: 26661925
[TBL] [Abstract][Full Text] [Related]
25. 9p21 locus analysis in high-risk gastrointestinal stromal tumors characterized for c-kit and platelet-derived growth factor receptor alpha gene alterations.
Perrone F; Tamborini E; Dagrada GP; Colombo F; Bonadiman L; Albertini V; Lagonigro MS; Gabanti E; Caramuta S; Greco A; Torre GD; Gronchi A; Pierotti MA; Pilotti S
Cancer; 2005 Jul; 104(1):159-69. PubMed ID: 15929122
[TBL] [Abstract][Full Text] [Related]
26. A melanoma-predisposing germline CDKN2A mutation with functional significance for both p16 and p14ARF.
Hashemi J; Lindström MS; Asker C; Platz A; Hansson J; Wiman KG
Cancer Lett; 2002 Jun; 180(2):211-21. PubMed ID: 12175554
[TBL] [Abstract][Full Text] [Related]
27. Combined analysis of p53 and RB pathways in epithelial ovarian cancer.
Hashiguchi Y; Tsuda H; Yamamoto K; Inoue T; Ishiko O; Ogita S
Hum Pathol; 2001 Sep; 32(9):988-96. PubMed ID: 11567230
[TBL] [Abstract][Full Text] [Related]
28. The
Han M; Yamaguchi S; Onishi M; Fujii T; Hosoya M; Wen X; Kido H; Kato S
Anticancer Res; 2022 May; 42(5):2277-2288. PubMed ID: 35489754
[TBL] [Abstract][Full Text] [Related]
29. MDM2 overexpression is associated with short survival in adults with medulloblastoma.
Giordana MT; Duó D; Gasverde S; Trevisan E; Boghi A; Morra I; Pradotto L; Mauro A; Chió A
Neuro Oncol; 2002 Apr; 4(2):115-22. PubMed ID: 11916503
[TBL] [Abstract][Full Text] [Related]
30. TP53 and CDKN2a mutations in never-smoker oral tongue squamous cell carcinoma.
Heaton CM; Durr ML; Tetsu O; van Zante A; Wang SJ
Laryngoscope; 2014 Jul; 124(7):E267-73. PubMed ID: 24431303
[TBL] [Abstract][Full Text] [Related]
31. [Interactive pathway of ARF-mdm2-p53].
Lin J; Zhu MH
Ai Zheng; 2003 Mar; 22(3):328-30. PubMed ID: 12654198
[TBL] [Abstract][Full Text] [Related]
32. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
Pilotti S; Della Torre G; Lavarino C; Di Palma S; Sozzi G; Minoletti F; Rao S; Pasquini G; Azzarelli A; Rilke F; Pierotti MA
J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
[TBL] [Abstract][Full Text] [Related]
33. Inactivation of the INK4A/ARF locus frequently coexists with TP53 mutations in non-small cell lung cancer.
Sanchez-Cespedes M; Reed AL; Buta M; Wu L; Westra WH; Herman JG; Yang SC; Jen J; Sidransky D
Oncogene; 1999 Oct; 18(43):5843-9. PubMed ID: 10557071
[TBL] [Abstract][Full Text] [Related]
34. Frequent inactivation of CDKN2A and rare mutation of TP53 in PCNSL.
Cobbers JM; Wolter M; Reifenberger J; Ring GU; Jessen F; An HX; Niederacher D; Schmidt EE; Ichimura K; Floeth F; Kirsch L; Borchard F; Louis DN; Collins VP; Reifenberger G
Brain Pathol; 1998 Apr; 8(2):263-76. PubMed ID: 9546285
[TBL] [Abstract][Full Text] [Related]
35. Molecular abnormalities of p53, MDM2, and H-ras in synovial sarcoma.
Oda Y; Sakamoto A; Satio T; Kawauchi S; Iwamoto Y; Tsuneyoshi M
Mod Pathol; 2000 Sep; 13(9):994-1004. PubMed ID: 11007040
[TBL] [Abstract][Full Text] [Related]
36. Tumoral TP53 and/or CDKN2A alterations are not reliable prognostic biomarkers in patients with localized Ewing sarcoma: a report from the Children's Oncology Group.
Lerman DM; Monument MJ; McIlvaine E; Liu XQ; Huang D; Monovich L; Beeler N; Gorlick RG; Marina NM; Womer RB; Bridge JA; Krailo MD; Randall RL; Lessnick SL;
Pediatr Blood Cancer; 2015 May; 62(5):759-65. PubMed ID: 25464386
[TBL] [Abstract][Full Text] [Related]
37. Detection and Correlation of Single and Concomitant
Pessôa IA; Amorim CK; Ferreira WAS; Sagica F; Brito JR; Othman M; Meyer B; Liehr T; de Oliveira EHC
Int J Mol Sci; 2019 May; 20(11):. PubMed ID: 31151164
[TBL] [Abstract][Full Text] [Related]
38. p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.
Lindström MS; Klangby U; Wiman KG
Oncogene; 2001 Apr; 20(17):2171-7. PubMed ID: 11360201
[TBL] [Abstract][Full Text] [Related]
39. TP53 mutations and mdm2 protein overexpression in cholangiocarcinomas.
Della Torre G; Pasquini G; Pilotti S; Alasio L; Civelli E; Cozzi G; Milella M; Salvetti M; Pierotti MA; Severini A
Diagn Mol Pathol; 2000 Mar; 9(1):41-6. PubMed ID: 10718212
[TBL] [Abstract][Full Text] [Related]
40. Molecular and immunohistochemical analysis of the prognostic value of cell-cycle regulators in urothelial neoplasms of the bladder.
Yurakh AO; Ramos D; Calabuig-Fariñas S; López-Guerrero JA; Rubio J; Solsona E; Romanenko AM; Vozianov AF; Pellin A; Llombart-Bosch A
Eur Urol; 2006 Sep; 50(3):506-15; discussion 515. PubMed ID: 16624482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
